Natural Proteolytic Processing of Hemofiltrate CC Chemokine 1 Generates a Potent CC Chemokine Receptor (CCR)1 and CCR5 Agonist with Anti-HIV Properties

Overview

Journal J Exp Med

Specialties Allergy & Immunology
General Medicine

Date 2000 Nov 21

PMID 11085751

Citations 39

Authors

M Detheux

L Standker

J Vakili

J Munch

U Forssmann

K Adermann

S Pohlmann

G Vassart

F Kirchhoff

M Parmentier

W G Forssmann

Affiliations

Soon will be listed here.

Abstract

Hemofiltrate CC chemokine (HCC)-1 is a recently described human chemokine that is constitutively expressed in numerous tissues and is present at high concentrations in normal plasma. Using a cell line expressing CC chemokine receptor (CCR)5 as a bioassay, we isolated from human hemofiltrate an HCC-1 variant lacking the first eight amino acids. HCC-1[9-74] was a potent agonist of CCR1, CCR3, and CCR5 and promoted calcium flux and chemotaxis of T lymphoblasts, monocytes, and eosinophils. It also blocked entry of HIV-1 strains using CCR5 as coreceptor. Limited tryptic digestion of HCC-1 generated the active variant. Conditioned media from several tumor cell lines activated HCC-1 with a high efficiency, and this activity could be inhibited by serine protease inhibitors. Our results indicate that HCC-1 represents a nonfunctional precursor that can be rapidly converted to the active chemokine by proteolytic processing. This process represents an additional mechanism by which tumor cells might generate chemoattractant molecules and recruit inflammatory cells. It might also affect HIV-1 replication in infected individuals and play an important role in AIDS pathogenesis.

Citing Articles

The chemokine CCL14 is a potential biomarker associated with immune cell infiltration in lung adenocarcinoma.

Sun B, Yuan Z, Wang M, Xu L, Feng J, Chen J Discov Oncol. 2024; 15(1):293.

PMID: 39030403 PMC: 11264474. DOI: 10.1007/s12672-024-01160-4.

Chemokine ligand 14 correlates with immune cell infiltration in the gastric cancer microenvironment in predicting unfavorable prognosis.

Lu B, Shi J, Cheng T, Wang C, Xu M, Sun P Front Pharmacol. 2024; 15:1397656.

PMID: 38887558 PMC: 11180770. DOI: 10.3389/fphar.2024.1397656.

Analysis of urinary C-C motif chemokine ligand 14 (CCL14) and first-generation urinary biomarkers for predicting renal recovery from acute kidney injury: a prospective exploratory study.

Qian B, Jia H, Weng Y, Li X, Chen C, Guo F J Intensive Care. 2023; 11(1):11.

PMID: 36941674 PMC: 10026399. DOI: 10.1186/s40560-023-00659-2.

Performance of a Standardized Clinical Assay for Urinary C-C Motif Chemokine Ligand 14 (CCL14) for Persistent Severe Acute Kidney Injury.

Koyner J, Chawla L, Bihorac A, Gunnerson K, Schroeder R, Demirjian S Kidney360. 2022; 3(7):1158-1168.

PMID: 35919538 PMC: 9337886. DOI: 10.34067/KID.0008002021.

Endogenous Peptide Inhibitors of HIV Entry.

Harms M, Hayn M, Zech F, Kirchhoff F, Munch J Adv Exp Med Biol. 2022; 1366:65-85.

PMID: 35412135 DOI: 10.1007/978-981-16-8702-0_5.

References

Charneau P, Mirambeau G, Roux P, Paulous S, Buc H, Clavel F . HIV-1 reverse transcription. A termination step at the center of the genome. J Mol Biol. 1994; 241(5):651-62. DOI: 10.1006/jmbi.1994.1542. View

Bleul C, Wu L, Hoxie J, Springer T, Mackay C . The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci U S A. 1997; 94(5):1925-30. PMC: 20019. DOI: 10.1073/pnas.94.5.1925. View

Forssmann U, Uguccioni M, Loetscher P, Dahinden C, Langen H, Thelen M . Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes. J Exp Med. 1997; 185(12):2171-6. PMC: 2196360. DOI: 10.1084/jem.185.12.2171. View

Schulz-Knappe P, Schrader M, Standker L, Richter R, Hess R, Jurgens M . Peptide bank generated by large-scale preparation of circulating human peptides. J Chromatogr A. 1997; 776(1):125-32. DOI: 10.1016/s0021-9673(97)00152-0. View

Stables J, Green A, Marshall F, Fraser N, Knight E, Sautel M . A bioluminescent assay for agonist activity at potentially any G-protein-coupled receptor. Anal Biochem. 1997; 252(1):115-26. DOI: 10.1006/abio.1997.2308. View

Weissman D, Rabin R, Arthos J, Rubbert A, Dybul M, Swofford R . Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor. Nature. 1997; 389(6654):981-5. DOI: 10.1038/40173. View

Oravecz T, Pall M, Roderiquez G, Gorrell M, Ditto M, Nguyen N . Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med. 1998; 186(11):1865-72. PMC: 2199148. DOI: 10.1084/jem.186.11.1865. View

Malnati M, Tambussi G, Clerici E, Polo S, Algeri M, Nardese V . Increased plasma levels of the C-C chemokine RANTES in patients with primary HIV-1 infection. J Biol Regul Homeost Agents. 1997; 11(1-2):40-2. View

Loetscher P, Uguccioni M, BORDOLI L, Baggiolini M, Moser B, Chizzolini C . CCR5 is characteristic of Th1 lymphocytes. Nature. 1998; 391(6665):344-5. DOI: 10.1038/34814. View

10.

Zagury D, Lachgar A, Chams V, Fall L, Bernard J, Zagury J . C-C chemokines, pivotal in protection against HIV type 1 infection. Proc Natl Acad Sci U S A. 1998; 95(7):3857-61. PMC: 19927. DOI: 10.1073/pnas.95.7.3857. View

11.

Mack M, Luckow B, Nelson P, Cihak J, Simmons G, Clapham P . Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J Exp Med. 1998; 187(8):1215-24. PMC: 2212227. DOI: 10.1084/jem.187.8.1215. View

12.

Pardigol A, Forssmann U, Zucht H, Loetscher P, Schulz-Knappe P, Baggiolini M . HCC-2, a human chemokine: gene structure, expression pattern, and biological activity. Proc Natl Acad Sci U S A. 1998; 95(11):6308-13. PMC: 27666. DOI: 10.1073/pnas.95.11.6308. View

13.

Tsou C, Gladue R, Carroll L, Paradis T, Boyd J, NELSON R . Identification of C-C chemokine receptor 1 (CCR1) as the monocyte hemofiltrate C-C chemokine (HCC)-1 receptor. J Exp Med. 1998; 188(3):603-8. PMC: 2212473. DOI: 10.1084/jem.188.3.603. View

14.

Ward S, Bacon K, Westwick J . Chemokines and T lymphocytes: more than an attraction. Immunity. 1998; 9(1):1-11. DOI: 10.1016/s1074-7613(00)80583-x. View

15.

Kinter A, Catanzaro A, Monaco J, Ruiz M, Justement J, Moir S . CC-chemokines enhance the replication of T-tropic strains of HIV-1 in CD4(+) T cells: role of signal transduction. Proc Natl Acad Sci U S A. 1998; 95(20):11880-5. PMC: 21734. DOI: 10.1073/pnas.95.20.11880. View

16.

Wang J, Deng X, Gong W, Su S . Chemokines and their role in tumor growth and metastasis. J Immunol Methods. 1998; 220(1-2):1-17. DOI: 10.1016/s0022-1759(98)00128-8. View

17.

Festuccia C, Dolo V, Guerra F, Violini S, Muzi P, Pavan A . Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells. Clin Exp Metastasis. 1999; 16(6):513-28. DOI: 10.1023/a:1006590217724. View

18.

Sabroe I, Hartnell A, Jopling L, Bel S, Ponath P, Pease J . Differential regulation of eosinophil chemokine signaling via CCR3 and non-CCR3 pathways. J Immunol. 1999; 162(5):2946-55. View

19.

Mosier D, Picchio G, Gulizia R, Sabbe R, Poignard P, Picard L . Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J Virol. 1999; 73(5):3544-50. PMC: 104126. DOI: 10.1128/JVI.73.5.3544-3550.1999. View

20.

Struyf S, Proost P, Schols D, De Clercq E, Opdenakker G, Lenaerts J . CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3. J Immunol. 1999; 162(8):4903-9. View